Skip to content
GLP-1 Scorecard
Menu
Site position #405

Evernow

Published by GLP-1 ScorecardUpdated

Evernow is a women's-focused, menopause-centered telehealth platform that prescribes branded GLP-1 weight loss medications including Ozempic, Wegovy, Zepbound, and Mounjaro via US-licensed clinicians.

Visit EvernowWe may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Semaglutide
Not disclosed
Tirzepatide
Not disclosed
Coverage
Coverage not published
Brand-name
Yes

Line Evernow up against its closest alternatives.

Factor breakdown

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and policies may differ from those used in the marks. See the methodology.

Cost value45/100
Dose & formulation53/100
Clinical oversight83/100
Labs & monitoring53/100
Fulfillment67/100
Contract terms55/100

Strengths

  • Prescribes FDA-approved branded GLP-1s, not compounded
  • Accepts insurance for video visits (BCBS, Anthem, UnitedHealthcare, Aetna)
  • Integrates GLP-1 weight loss with menopause and HRT care
  • Flexible one-time visit or low-cost membership models

What to consider

  • Weight loss is one vertical alongside menopause and HRT care
  • GLP-1 medication cost depends on insurance and is not posted
  • State availability not specified on the site

Bottom line — Grade C

Best for: Women wanting insurance-covered branded GLP-1 weight loss alongside menopause and HRT care.

Site position #405 of 541. Commercial relationships affect placement, not the score. See our featured provider, CoreAge Rx (#1), for comparison.

Closest here

The rankings grading nearest Evernow — the realistic shortlist.

The 19 rankings nearest this one

View full scorecard rankings →

Pricing/verification reflect Evernow's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on Evernow's site. Not medical advice; see our disclosure.

← Back to the scorecard